1
|
Teofili L, Papacci P, Orlando N, Bianchi M, Pasciuto T, Mozzetta I, Palluzzi F, Giacò L, Giannantonio C, Remaschi G, Santosuosso M, Beccastrini E, Fabbri M, Valentini CG, Bonfini T, Cloclite E, Accorsi P, Dragonetti A, Cresi F, Ansaldi G, Raffaeli G, Villa S, Pucci G, Mondello I, Santodirocco M, Ghirardello S, Vento G. BORN study: a multicenter randomized trial investigating cord blood red blood cell transfusions to reduce the severity of retinopathy of prematurity in extremely low gestational age neonates. Trials 2022; 23:1010. [PMID: 36514106 PMCID: PMC9746198 DOI: 10.1186/s13063-022-06949-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Accepted: 11/22/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Extremely low gestational age neonates (ELGANs, i.e., neonates born before 28 weeks of gestation) are at high risk of developing retinopathy of prematurity (ROP), with potential long-life visual impairment. Due to concomitant anemia, ELGANs need repeated red blood cell (RBC) transfusions. These produce a progressive replacement of fetal hemoglobin (HbF) by adult hemoglobin (HbA). Furthermore, a close association exists between low levels of HbF and severe ROP, suggesting that a perturbation of the HbF-mediated oxygen release may derange retinal angiogenesis and promote ROP. METHODS/DESIGN BORN (umBilical blOod to tRansfuse preterm Neonates) is a multicenter double-blinded randomized controlled trial in ELGANs, to assess the effect of allogeneic cord blood RBC transfusions (CB-RBCs) on severe ROP development. Recruitment, consent, and randomization take place at 10 neonatology intensive care units (NICUs) of 8 Italian tertiary hospitals. ELGANs with gestational age at birth comprised between 24+0 and 27+6 weeks are randomly allocated into two groups: (1) standard RBC transfusions (adult-RBCs) (control arm) and (2) CB-RBCs (intervention arm). In case of transfusion need, enrolled patients receive transfusions according to the allocation arm, unless an ABO/RhD CB-RBC is unavailable. Nine Italian public CB banks cooperate to make available a suitable amount of CB-RBC units for all participating NICUs. The primary outcome is the incidence of severe ROP (stage 3 or higher) at discharge or 40 weeks of postmenstrual age, which occurs first. DISCUSSION BORN is a groundbreaking trial, pioneering a new transfusion approach dedicated to ELGANs at high risk for severe ROP. In previous non-randomized trials, this transfusion approach was proven feasible and able to prevent the HbF decrease in patients requiring multiple transfusions. Should the BORN trial confirm the efficacy of CB-RBCs in reducing ROP severity, this transfusion strategy would become the preferential blood product to be used in severely preterm neonates. TRIAL REGISTRATION ClinicalTrials.gov NCT05100212. Registered on October 29, 2021.
Collapse
Affiliation(s)
- Luciana Teofili
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy ,grid.8142.f0000 0001 0941 3192Università Cattolica del Sacro Cuore, Rome, Italy
| | - Patrizia Papacci
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy ,grid.8142.f0000 0001 0941 3192Università Cattolica del Sacro Cuore, Rome, Italy
| | - Nicoletta Orlando
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Maria Bianchi
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Tina Pasciuto
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Iolanda Mozzetta
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Fernando Palluzzi
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Luciano Giacò
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Carmen Giannantonio
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy
| | - Giulia Remaschi
- grid.24704.350000 0004 1759 9494Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Michela Santosuosso
- grid.24704.350000 0004 1759 9494Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Enrico Beccastrini
- grid.24704.350000 0004 1759 9494Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Marco Fabbri
- grid.144189.10000 0004 1756 8209Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | | | - Tiziana Bonfini
- Azienda Sanitaria Locale-Presidio Ospedaliero di Pescara, Pescara, Italy
| | - Eleonora Cloclite
- Azienda Sanitaria Locale-Presidio Ospedaliero di Pescara, Pescara, Italy
| | - Patrizia Accorsi
- Azienda Sanitaria Locale-Presidio Ospedaliero di Pescara, Pescara, Italy
| | | | - Francesco Cresi
- Città della Salute e della Scienza, Turin, Italy ,grid.7605.40000 0001 2336 6580Department of Public Health and Pediatrics, University of Turin, Turin, Italy
| | | | - Genny Raffaeli
- grid.414818.00000 0004 1757 8749Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy ,grid.4708.b0000 0004 1757 2822Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Stefania Villa
- grid.414818.00000 0004 1757 8749Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Giulia Pucci
- grid.414504.00000 0000 9051 0784Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - Isabella Mondello
- grid.414504.00000 0000 9051 0784Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
| | - Michele Santodirocco
- grid.413503.00000 0004 1757 9135Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - Stefano Ghirardello
- grid.419425.f0000 0004 1760 3027Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
| | - Giovanni Vento
- grid.414603.4Fondazione Policlinico A. Gemelli IRCCS, Largo Gemelli 8, 00168 Rome, Italy ,grid.8142.f0000 0001 0941 3192Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
2
|
Di Pietrantonio N, Shumliakivska M, Suades R, Di Tomo P, Bonfini T, Pandolfi A, Cosentino F. Epigenetic regulation of oxidative and inflammatory phenotypes in women with gestational diabetes and offspring. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Hyperglycemia-induced oxidative stress and inflammation are potent drivers of atherosclerotic cardiovascular disease (ASCVD). Gestational diabetes (GDM) is characterized by chronic hyperglycemia during pregnancy and may represent a clinical model to study the mechanisms of oxidative stress and inflammation induced by hyperglycemia. GDM is associated with a range of adverse perinatal and long-term outcomes for both mother and offspring. In this perspective, it is emerging a putative association between maternal GDM and offspring's epigenetic trait.
Purpose
To investigate the link between histone modifications, oxidative stress and inflammatory phenotype as well as the transmission of epigenetic signatures to the offspring.
Methods
We analyzed peripheral blood mononuclear cells (PBMC) from GDM and control mothers as well as human umbilical vein endothelial cells (HUVEC) and cord blood mononuclear cells (CBMC) isolated from newborn umbilical cords obtained at delivery from both groups. Histone methyltransferase MLL1-dependent trimethylation of histone 3 at lysine 4 amino residue (H3K4me3) on NF-kB p65 subunit promoter region was assessed by chromatin immunoprecipitation (ChIP) and real-time qPCR in HUVEC, PBMC and CBMC, respectively. MLL1 and downstream inflammatory and redox genes were determined by real-time qPCR and immunocytochemistry in the presence and in the absence of MLL1 inhibitor MM-102. Measurement of reactive oxygen species (ROS) was performed by electron spin resonance spectroscopy.
Results
For the first time, we demonstrated a significant increase of MLL1 expression with subsequent MLL1-induced upregulation of NF-kB p65 gene via H3K4me3 in GDM as compared to control cells. MLL1-driven epigenetic remodeling of NF-kB p65 promoter is upstream to the activation of inflammatory pathway. Indeed, treatment with MM-102 decreased H3K4me3 and blunted expression of NF-kB p65 as well as VCAM-1, MCP-1 and IL-6 genes. We also found that expression of ROS scavenger aldehyde dehydrogenase 2 is reduced, whereas pro-oxidant nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit NOX4 is upregulated. Interestingly, the increased ROS generation observed in GDM is involved in the upregulation of MLL1 as shown by the restoring effect of antioxidant vitamin C on MLL1 expression levels.
Conclusions
Our results suggest that a complex interplay between oxidative stress and histone modifications are responsible for the GDM maternal inflammatory and oxidative phenotypes and its transmission to the offspring. The deciphering of epigenetic-induced chromatin remodelling opens the perspective for pharmacological reprogramming of adverse chromatin changes to reduce the burden of early development of metabolic phenotypes and ASCVD.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): University G. d'Annunzio MIUR fundings Schematic figure
Collapse
Affiliation(s)
- N Di Pietrantonio
- G. d Annunzio University, Department of Medical, Oral and Biotechnological Sciences, CAST (ex CeSI-MeT), Chieti, Italy
| | - M Shumliakivska
- Karolinska Institute, Cardiology Unit, Department of Medicine, Stockholm, Sweden
| | - R Suades
- Karolinska Institute, Cardiology Unit, Department of Medicine, Stockholm, Sweden
| | - P Di Tomo
- G. d Annunzio University, Department of Medical, Oral and Biotechnological Sciences, CAST (ex CeSI-MeT), Chieti, Italy
| | - T Bonfini
- Hospital Spirito Santo, Department of Oncology Hematology, Pescara, Italy
| | - A Pandolfi
- G. d Annunzio University, Department of Medical, Oral and Biotechnological Sciences, CAST (ex CeSI-MeT), Chieti, Italy
| | - F Cosentino
- Karolinska Institute, Cardiology Unit, Department of Medicine, Stockholm, Sweden
| |
Collapse
|
3
|
Ulbar F, Villanova I, Giancola R, Baldoni S, Guardalupi F, Fabi B, Olioso P, Capone A, Sola R, Ciardelli S, Del Papa B, Brattelli A, Ricciardi I, Taricani S, Sabbatinelli G, Iuliani O, Passeri C, Sportoletti P, Santarone S, Pierini A, Calabrese G, Falzetti F, Bonfini T, Accorsi P, Ruggeri L, Martelli MF, Velardi A, Di Ianni M. Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35. Biol Blood Marrow Transplant 2020; 26:2204-2210. [PMID: 32961369 DOI: 10.1016/j.bbmt.2020.08.034] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 08/31/2020] [Accepted: 08/31/2020] [Indexed: 02/06/2023]
Abstract
In the setting of T cell-depleted, full-haplotype mismatched transplantation, adoptive immunotherapy with regulatory T cells (Tregs) and conventional T cells (Tcons) can prevent graft-versus-host disease (GVHD) and improve post-transplantation immunologic reconstitution and is associated with a powerful graft-versus-leukemia effect. To improve the purity and the quantity of the infused Tregs, good manufacturing practices (GMP)-compatible expansion protocols are needed. Here we expanded Tregs using an automated, clinical-grade protocol. Cells were extensively characterized in vitro, and their efficiency was tested in vivo in a mouse model. Tregs were selected by CliniMacs (CD4+CD25+, 94.5 ± 6.3%; FoxP3+, 63.7 ± 11.5%; CD127+, 20 ± 3%; suppressive activity, 60 ± 7%), and an aliquot of 100 × 106 was expanded for 14 days using the CliniMACS Prodigy System, obtaining 684 ± 279 × 106 cells (CD4+CD25+, 99.6 ± 0.2%; FoxP3+, 82 ± 8%; CD127+, 1.1 ± 0.8%; suppressive activity, 75 ± 12%). CD39 and CTLA4 expression levels increased from 22.4 ± 12% to 58.1 ± 13.3% (P < .05) and from 20.4 ± 6.7% to 85.4 ± 9.8% (P < .01), respectively. TIM3 levels increased from .4 ± .05% to 29 ± 16% (P < .05). Memory Tregs were the prevalent population, whereas naive Tregs almost disappeared at the end of the culture. mRNA analysis displayed significant increases in CD39, IL-10, granzyme B, and IL-35 levels at the end of culture period (P < .05). Conversely, IFNγ expression decreased significantly by day +14. Expanded Tregs were sorted according to TIM3, CD39, and CD62L expression levels (purity >95%). When sorted populations were analyzed, TIM3+ cells showed significant increases in IL-10 and granzyme B (P < .01) .When expanded Tregs were infused in an NSG murine model, mice that received Tcons only died of GVHD, whereas mice that received both Tcons and Tregs survived without GVHD. GMP grade expanded cells that display phenotypic and functional Treg characteristics can be obtained using a fully automated system. Treg suppression is mediated by multiple overlapping mechanisms (eg, CTLA-4, CD39, IL-10, IL-35, TGF-β, granzyme B). TIM3+ cells emerge as a potentially highly suppressive population. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Collapse
Affiliation(s)
- Francesca Ulbar
- Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Ida Villanova
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | | | - Stefano Baldoni
- Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Francesco Guardalupi
- Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Bianca Fabi
- Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Paola Olioso
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Anita Capone
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Rosaria Sola
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Sara Ciardelli
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Beatrice Del Papa
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | | | - Ilda Ricciardi
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Stefano Taricani
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Giulia Sabbatinelli
- Department of Neurosciences, Imaging and Clinical Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Ornella Iuliani
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Cecilia Passeri
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Paolo Sportoletti
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Stella Santarone
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Antonio Pierini
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Giuseppe Calabrese
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy; Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Pescara, Italy
| | - Franca Falzetti
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Tiziana Bonfini
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Patrizia Accorsi
- Department of Oncology Hematology, Pescara Hospital, Pescara, Italy
| | - Loredana Ruggeri
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Massimo Fabrizio Martelli
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Andrea Velardi
- Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
| | - Mauro Di Ianni
- Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy; Department of Oncology Hematology, Pescara Hospital, Pescara, Italy.
| |
Collapse
|
4
|
Angelini A, Accorsi P, Iacone A, Bonfini T, Refè C, Olivieri A, Bodini U, Bergonzi C, Incarbone E, Adorno G, Bertola F, Fattori G, Torlontano G. Concentration of Human Hematopoietic Stem Cells in Bone Marrow Transplantation: Results of a Multicenter Study Using Baxter CS 3000 plus Cell Separator. Int J Artif Organs 2018. [DOI: 10.1177/039139889301605s03] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Preliminary BM processing to produce an enriched MNC fraction from large BM volumes improves subsequent pharmacological and/or immunological “ex vivo” treatment and cryopreservation. We detail on a multicenter study (6 Transplant Centers) performed to establish an effective and reliable protocol using a CS 3000 continuous flow separator on a large series of BM processed for autologous (96) and allogeneic (12) transplantation. The reduction in volume was 78.6+7.2% while 28.9+12.4% of the original nucleated cells were found in the final product. A mean of 84.3+13.2% of the starting MNC was yielded in a fraction containing over 81% MNC. Cloning efficiency indicated than the final graft was highly enriched in progenitor cells committed to the granulocyte/macrophage pathway (> 100%) as assessed in vitro (CFU-GM). Removal of RBC and PLT was 98.3+1.1 and 37.7+14.6%, respectively. The mean dose of MNC and CFU-GM was 0.6+0.37 x 108 and 0.96+1 x 108 recipient weight. The entire process was accomplished in 87.5+20 min. We concluded that this automated device is a simple and reproducible method for BM processing suitable as first step for further “ex vivo” automated negative and/or positive cell selections.
Collapse
Affiliation(s)
- A. Angelini
- Hematology Department and Blood Transfusion Centre, Pescara
- Chair of Hematology, G. D'Annunzio University, Chieti
| | - P. Accorsi
- Hematology Department and Blood Transfusion Centre, Pescara
| | - A. Iacone
- Hematology Department and Blood Transfusion Centre, Pescara
| | - T. Bonfini
- Hematology Department and Blood Transfusion Centre, Pescara
- Chair of Hematology, G. D'Annunzio University, Chieti
| | - C. Refè
- Regional Blood Transfusion Centre, Torrette Hospital, Ancona
| | | | - U. Bodini
- Blood Transfusion Centre, “Maggiore” Hospital, Cremona
| | - C. Bergonzi
- Department of Bone Marrow Transplantation and Hematology, “Maggiore” Hospital, Cremona
| | - E. Incarbone
- Immunohematology and Blood Transfusion Centre, Regina Margherita, Pediatric Hospital, Torino
| | - G. Adorno
- Chair of Hematology, Tor Vergata University, Roma
| | - F. Bertola
- Blood Transfusion Centre, Civil Hospital, Vicenza
| | | | - G. Torlontano
- Hematology Department and Blood Transfusion Centre, Pescara
- Chair of Hematology, G. D'Annunzio University, Chieti
- I.R.C.C.S. S. Giovanni Rotondo, Foggia - Italy
| |
Collapse
|
5
|
Manzardo C, Tamburini A, De Meis I, Bonfini T, Di Marzio I, Liberatore E, Vacca M, Pierelli L. A comparison between three different centers for clinical risk assessment in cord blood banking activities by FMEA methodology. Transfus Apher Sci 2014. [DOI: 10.1016/s1473-0502(14)50049-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Savini V, Bonfini T, Marrollo R, Argentieri AV, Riccioni S, Astolfi D, Fazii P, D'Antonio D, Gherardi G. Enterococcus hirae: a zoonotic microorganism in human umbilical cord blood. World J Microbiol Biotechnol 2013; 30:1423-6. [PMID: 24197782 DOI: 10.1007/s11274-013-1537-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2013] [Accepted: 10/22/2013] [Indexed: 11/29/2022]
Abstract
Enterococcus hirae is rarely collected from man, while it is a common pathogen in mammals and birds. We describe the first isolation of the organism (strain DSM 27815) from human umbilical cord blood (UCB), thus emphasizing the risk of contamination of UCB units for clinical use. In this context, we also highlight the importance of an extensive training of the collecting personnel as to the observance of the disinfection protocol ensuring UCB units sterility.
Collapse
Affiliation(s)
- Vincenzo Savini
- Clinical Microbiology and Virology, Spirito Santo Hospital, Via Fonte Romana 8, CAP 65124, Pescara, PE, Italy,
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mastrangelo D, Massai L, Fioritoni G, Iacone A, Bartolomeo PD, Accorsi P, Bonfini T, Muscettola M, Grasso G. Megadoses of Sodium Ascorbate Efficiently Kill HL60 Cells <i>in Vitro</i>: Comparison with Arsenic Trioxide. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/jct.2013.48162] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
8
|
Giancola R, Accorsi P, Bonfini T, Catinella V, Iacone A. Flow citometry strategies to evaluate cryopreservation efficacy. Drugs Cell Ther Hematol 2012. [DOI: 10.4081/dcth.2012.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
9
|
Giancola R, Accorsi P, Bonfini T, Catinella V, Iacone A. Flow citometry strategies to evaluate cryopreservation efficacy. Drugs Cell Ther Hematol 2012. [DOI: 10.4081/dcth.2012.1s.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
10
|
Giancola R, Bonfini T, Iacone A. Cell therapy: cGMP facilities and manufacturing. Muscles Ligaments Tendons J 2012; 2:243-7. [PMID: 23738304 PMCID: PMC3666518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Advanced therapies constitute one of the most complex, organizational, and regulatory areas currently approached by clinical researchers in order to explore new therapeutic applications. Basic scientists and clinicians trying to implement cell therapies into clinical practice, may feel overwhelmed by the apparently endless regulatory requirements that apply. However, regulatory agencies have primary responsibility on patient safety and law enforcement are, and should be, their main considerations. Cell- and tissue-based therapies have the potential to treat many conditions, where present conventional treatments are inadequate. The current approach to cell- and tissue-based therapy development requires using good manufacturing production facilities through master and working cell banks. Facilities need to be purpose-designed and accredited by their national medicinal regulatory body and production scientists need to work in close tandem with quality assurances and ethics committees to absolutely ensure the safety of this cellular products.
Collapse
Affiliation(s)
| | - Tiziana Bonfini
- Department of Transfusion Medicine, Pescara Civil Hospital, Italy
| | - Antonio Iacone
- Department of Transfusion Medicine, Pescara Civil Hospital, Italy
| |
Collapse
|
11
|
Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers FWMB, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontão-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Arvola A, Humpe A, Buwitt-Beckmann U, Wiesneth M, Schauwecker P, Schrezenmeier H, Bönig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey R, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S. Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow). Vox Sang 2011; 101:255-75. [DOI: 10.1111/j.1423-0410.2011.01471.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Di Baldassarre A, Di Rico M, Di Noia A, Bonfini T, Iacone A, Marchisio M, Miscia S, Alfani E, Migliaccio AR, Stamatoyannopoulos G, Migliaccio G. Protein kinase Calpha is differentially activated during neonatal and adult erythropoiesis and favors expression of a reporter gene under the control of the (A)gamma globin-promoter in cellular models of hemoglobin switching. J Cell Biochem 2007; 101:411-24. [PMID: 17212360 DOI: 10.1002/jcb.21189] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
PKCalpha was found to be expressed (mRNA and protein) throughout the in vitro maturation of primary human erythroblasts but its activity (phosphorylation levels and nuclear localization) was consistently higher in cells derived from human neonatal rather than adult blood. Since the gamma/gamma + beta globin expression ratio represented the major difference between neonatal and adult erythroblasts (58 +/- 12 vs. 7 +/- 3, respectively), we tested the hypothesis that PKCalpha might affect gamma-globin expression by measuring the levels of (A)gamma- or beta-promoter-driven reporter activity in erythroid cells stably (GM979) or transiently (K562, primary adult and neonatal erythroblasts) transfected with a dual microLCRbetaprRluc(A)gammaprFluc reporter in the presence of transient expression of either the constitutively active (sPKCalpha) or catalytically inactive (iPKCalpha) PKCalpha. As further control, GM979 cells were incubated with the PKC inhibitor rottlerin (30 microM). In all the cells analyzed, sPKCalpha significantly increased (by two- to sixfold) the levels of luciferase activity driven by the (A)gamma-promoter and the (A)gamma-F/((A)gamma-F + 2beta-R) expression ratio. In GM979 cells, rottlerin inhibited (by 50%) the (A)gamma-driven luciferase activity and the (A)gamma-F/((A)gamma-F + 2beta-R) expression ratio. These results suggest that different PKC isoforms may exert ontogenetic-specific functions in erythropoiesis and that modulation of PKCalpha might affect the activity of (A)gamma-promoter-driven reporters.
Collapse
|
13
|
Migliaccio A, Di Baldassarre A, Di Rico M, Di Noia A, Bonfini T, Iacone A, Marchisio M, Miscia S, Alfani E, Stamatoyannopoulos G, Migliaccio G. Protein kinase Cα induces expression of a reporter gene under the control of the Aγ globin-promoter in cellular models of hemoglobin switching. Blood Cells Mol Dis 2007. [DOI: 10.1016/j.bcmd.2006.10.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
14
|
Colosimo A, Guida V, Antonucci I, Bonfini T, Stuppia L, Dallapiccola B. Sequence-specific modification of a -thalassemia locus by small DNA fragments in human erythroid progenitor cells. Haematologica 2007; 92:129-30. [PMID: 17229648 DOI: 10.3324/haematol.10560] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Gene therapy has been proposed as a definitive cure of beta-thalassemia. We applied a gene targeting approach, based on the introduction of small DNA fragments (SDF) into erythroid progenitor cells, to specifically modify the beta-globin gene sequence at codon 39. The strategy was first tested in normal individuals by delivering mutant SDF that were able to produce the beta-39 (C->T) mutation. Secondly, wild-type SDF were electroporated into target cells of beta-3i9/beta-39 b-thalassemic patients to correct the endogenous mutation. In both cases, gene modification was assayed by allele-specific polymerase chain reaction of DNA and mRNA, by restriction fragment length polymorphism analysis and by direct sequencing.
Collapse
|
15
|
Astori G, Larghero J, Bonfini T, Giancola R, Di Riti M, Rodriguez L, Rodriguez M, Mambrini G, Bigi L, Lacone A, Marolleau JP, Panzani I, Garcia J, Querol S. Ex vivo expansion of umbilical cord blood CD34+ cells in a closed system: a multicentric study. Vox Sang 2006; 90:183-90. [PMID: 16507018 DOI: 10.1111/j.1423-0410.2006.00751.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND OBJECTIVES The Dideco 'Pluricell System' is a CE-marked medical device allowing haematopoietic stem cell (HSC) expansion. It comprises a kit of cGMP cytokines and reagents, a closed-cell expansion chamber and a cell-washing set. We tested the system in a multicentric study by expanding CD34(+) cells from eight fresh umbilical cord blood (UCB) samples. MATERIALS AND METHODS During culture, the mean nucleated cell (NC) count, the mean CD34(+) cell count, fold expansion, viability and apoptosis were measured. Clonogenic assays and immunophenotypical characterization were performed on days 0, 7 and 12. On the expanded cellular product, in three cases cell genotyping, endotoxin level and mycoplasma detection (by polymerase chain reaction) were performed. RESULTS The mean CD34(+) cell expansion on days 7 and 12 was sevenfold and 12-fold respectively and the mean NC expansion was 69-fold and 180-fold. The mean NC viability on day 12 was 96.9% (94.4-99.1). After 12 days, granulocyte-macrophage colony-forming units (GM-CFU) showed a 20-fold increase: a slight increase in CD34(+) cell apoptosis was observed during culture. In all of three cases neither chromosomal alterations nor mycoplasma contamination was detected. No significant endotoxin levels were detected after expansion. CONCLUSIONS The device allows the ex vivo expansion of NC and CD34(+) cells in a closed system. The expanded cellular product is a mixture of progenitors (CD34(+) cells) and differentiated (mainly myeloid and megakaryocytic) cells. To reduce cell apoptosis, more frequent cell feeding during culture should be tested.
Collapse
|
16
|
Sanchez M, Alfani E, Migliaccio AR, Bonfini T, Migliaccio G. Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2. Bone Marrow Transplant 2003; 31:713-23. [PMID: 12692612 DOI: 10.1038/sj.bmt.1703904] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We report the effects exerted by cytokine combinations, including stem cell factor (SCF), interleukin-7, interleukin-4 and interleukin-2, on the amplification of T cells from cord blood (CB) mononuclear cells cultured for 10-11 days under serum-deprived conditions. Of all the combinations investigated, SCF+interleukin-7 sustained the best fold increase (FI) of total nucleated cells (FI=6.4+/-1.17), amplifying preferentially CD4(+) over CD8(+) T-cell subsets (FI=4.72+/-0.79 vs 2.73+/-1.2, respectively, P<0.05). The addition of interleukin-2 to this combination did not significantly increase the total number of cells generated (FI=7.4+/-2.27), but allowed preferential amplification of CD8(+) over CD4(+) T cells (FI=6.04+/-0.14 vs 1.67+/-0.6, respectively, P<0.05). Single-strand conformation polymorphism analysis of the T-cell receptor V(beta)-chain rearrangements expressed by the expanded T cells indicated that the complexity of the T-cell repertoire had increased after 10 days of culture in the presence of SCF and IL-7. Interestingly, a modest expansion (FI=8.67+/-1.5) of myeloid progenitor cells was also observed in these cultures. These results indicate that it is possible to expand specific T-cell subsets for adoptive immunotherapy without losing myeloid progenitor cells necessary for neutrophil recovery after CB transplantation, by modulating the cytokines added to the cultures.
Collapse
Affiliation(s)
- M Sanchez
- Laboratory of Cell Biology, Istituto Superiore di Sanita, Rome, Italy
| | | | | | | | | |
Collapse
|
17
|
Accorsi P, Dell'Isola M, Bonfini T, Giancola R, Spadano A, Fioritoni G, Iacone A. Large volume leukapheresis with AMICUS cell separator in peripheral blood stem cell autologous transplant. Transfus Apher Sci 2001; 24:79-83. [PMID: 11515615 DOI: 10.1016/s0955-3886(00)00130-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- P Accorsi
- Department of Transfusion Medicine, Centro Studi E. Jucci Ciancarelli, Ospedale Civile, Pescara, Italy
| | | | | | | | | | | | | |
Collapse
|
18
|
Bonfini T, Accorsi P, Giancola R, Liberatore E, Dell'Isola M, Di Bartolomeo P, Fioritoni G, Iacone A. Kinetic of intraprocedure CD34+ cell release during pbsc collection in healthy donors. Exp Hematol 2000. [DOI: 10.1016/s0301-472x(00)00450-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Recchia F, Accorsi P, Bonfini T, De Filippis S, Grimaldi M, Corrao G, Rosselli M, Amiconi G, Iacone A, Rea S. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors. J Interferon Cytokine Res 2000; 20:171-7. [PMID: 10714552 DOI: 10.1089/107999000312577] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A trial was conducted to investigate whether the sequential administration of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) could accelerate reconstitution of hematopoiesis, compared with G-CSF alone following high-dose chemotherapy (HDCT). A group of 34 consecutive patients with solid tumors undergoing HDCT and autologous peripheral blood progenitor cell (PBPC) transplantation was studied. Conditioning regimen included carboplatin, etoposide, mitoxantrone, and melphalan for breast cancer and cyclophosphamide or ifosfamide, carboplatin, and etoposide for the other tumors. HDCT was delivered from day -3 to day -1. PBPC were infused on day 0, and on the same day growth factors were administered subcutaneously (s.c.) 5 microg/kg each. Seventeen patients were randomized to receive G-CSF from day 0 to day 13 after HDCT (arm A), and 17 patients received G-CSF from day 0 to day 6 and GM-CSF from day 7 to day 13 (arm B). Patients were stratified, and their characteristics were homogeneous in both arms for age, performance status, and number of previous chemotherapy courses and CD34+ infused. The median time to absolute neutrophil count (ANC) >500/microl was 10 days in arm A and 9 days in arm B (p = 0.96). Days to platelet (PLT) count >20,000 were not different in the two treatment arms (p = 0.1), but patients randomized to arm A had a lower platelet count compared with patients in arm B. One month after PBPC transplantation, a statistically significant difference in PLT count was observed (arm A median 150x10(3)/microl (90-310), arm B median 254x10(3)/microl (117-387),p = 0.0013). The days patients had fever >38 degrees C were 39 in arm A and 26 in arm B (p = 0.18). The difference in the length of hospital stay was not statistically significant between the groups (Mann-Whitney sum rank test). After a median follow-up of 30 months, 21 patients were alive and 20 were disease free. These data show that the two growth factors are associated with different patterns of hematopoietic recovery, and larger randomized trials in groups of more homogeneous patients will be needed to define the effects and benefits of combination growth factor therapies.
Collapse
Affiliation(s)
- F Recchia
- Division of Oncology, Civil Hospital-Avezzano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Accorsi P, Dell'isola M, Bonfini T, Valbonesi M, Avanzi G, Menichella G, Politi P, Salemme L, Iacone A. Plateletapheresis with the New Baxter-Amicus Blood Cell Separator: An Italian Multicenter Study. Int J Artif Organs 1998. [DOI: 10.1177/039139889802106s07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The efficiency and quality of platelet (PLT) collection were evaluated in a preliminary study using a new cell separator: Baxter-Amicus. The new fully automated blood cell separator combines centrifugation with elutration to obtain higher PLT efficiency with a lower white blood cell (WBC) contamination. We compared procedures performed with the first software version 2.13 and the more recent 2.37 version, then with and without plasma collection. Data from 262 plateletapheresis procedures were analyzed. The mean value of the PLT yield was 4.5±1.0x1011, collection efficiency: 69.4±12%; WBC contamination: 0.8±2.x106; and procedure time: 73± 19 minutes. The use of the new software vs the former permitted the collection of a higher number of platelets: 4.9± 1.1 vs. 4.5± 1.9 x1011 (=ns), with a lower WBC contamination: 0.6± 1.0 vs 0.7± 1.2 x106 (p=ns), in less time: 63± 10 vs 73± 19 minutes (p=0.002). The efficiency of platelet harvesting with simultaneous plasma collection was higher than the standard procedure: 73± 13 vs. 67± 10% (p=0.003).
Collapse
Affiliation(s)
- P. Accorsi
- Department of Hematology and Oncology and “Centro Studi E. Jucci Ciancarelli”, S. Spirito Hospital, Pescara
| | - M. Dell'isola
- Department of Hematology and Oncology and “Centro Studi E. Jucci Ciancarelli”, S. Spirito Hospital, Pescara
| | - T. Bonfini
- Department of Hematology and Oncology and “Centro Studi E. Jucci Ciancarelli”, S. Spirito Hospital, Pescara
- Department of Medicine and Science of Aging, Chair of Hematology, G. D'Annunzio University, Chieti
| | - M. Valbonesi
- Immunohematology Service S. Martino Hospital, Genova
| | - G. Avanzi
- Immunohematology Service Careggi Hospital, Firenze
| | | | - P. Politi
- Immunohematology Service S. Salvatore Hospital, Pesaro - Italy
| | - L. Salemme
- Department of Hematology and Oncology and “Centro Studi E. Jucci Ciancarelli”, S. Spirito Hospital, Pescara
| | - A. Iacone
- Department of Hematology and Oncology and “Centro Studi E. Jucci Ciancarelli”, S. Spirito Hospital, Pescara
| |
Collapse
|
21
|
Bonfini T, Accorsi P, Dell'isola M, Giancola R, Catinella V, D'Antonio D, Salemme L, Di Bartolomeo P, Davì G, Iacone A. Quality Assurance in Ex Vivo Progenitor Cell Manipulation. Int J Artif Organs 1998. [DOI: 10.1177/039139889802106s10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Over the past few years, hemopoietic transplant has evolved from an investigational phase to routine therapy, thus becoming a potentially curative strategy for a large variety of diseases. Several transplant situations are still outstanding and the need for ex vivo graft manipulation for different transplantation products is growing. To obtain an ideal graft, many different methods, even sophisticated manipulations, may be required. Since transplantation products play an important role in disease outcome, the assessment of graft quality to ensure standard compliance is needed. The development of a regulatory approach to these new manipulated hematopoietic products is very complex and should come under current Good Manufacturing Practices (cGMPs). Manufacturing approach to these new blood products must be urgently introduced to accounting Quality System in Transfusion Medicine. The best way to develop compliance with standards, in agreement with internationally accepted criteria, is, likely, an accreditation system in transplantation programs.
Collapse
Affiliation(s)
- T. Bonfini
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
- Department of Medicine and Science of Aging, Chair of Hematology, G. D'Annunzio University, Chieti
| | - P. Accorsi
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - M. Dell'isola
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - R. Giancola
- Department of Experimental Medicine, Clinical Pathology, “L'Aquila” University, L'Aquila - Italy
| | - V. Catinella
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - D. D'Antonio
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - L. Salemme
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - P. Di Bartolomeo
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| | - G. Davì
- Department of Medicine and Science of Aging, Chair of Hematology, G. D'Annunzio University, Chieti
| | - A. Iacone
- Department of Hematology and Oncology, and “Centro Studi E. Jucci Ciancarelli, S. Spirito Hospital, Pescara
| |
Collapse
|
22
|
D'Antonio D, Violante B, Mazzoni A, Bonfini T, Capuani MA, D'Aloia F, Iacone A, Schioppa F, Romano F. A nosocomial cluster of Candida inconspicua infections in patients with hematological malignancies. J Clin Microbiol 1998; 36:792-5. [PMID: 9508314 PMCID: PMC104627 DOI: 10.1128/jcm.36.3.792-795.1998] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Candida inconspicua was recovered from three patients with hematological malignancies. Two patients had intravenous-catheter-associated fungemia, whereas the third had fungal hepatitis. The three cases of infection occurred over a period of 1 month in patients staying in adjacent single rooms. In vitro susceptibility testing of fungal strains showed all isolates to be resistant to fluconazole, with MICs greater than 32 microg/ml. All of the strains had identical DNA restriction profiles and randomly amplified polymorphic DNA fingerprints. These data suggest a nosocomially acquired infection emanating from a common source within the hospital environment.
Collapse
Affiliation(s)
- D D'Antonio
- Dipartimento di Ematologia ed Oncologia, Ospedale Santo Spirito, Pescara, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
D'Antonio D, Iacone A, Schioppa FS, Bonfini T, Romano F. Effect of the current antimicrobial therapeutic strategy on fungal colonization in patients with hematologic malignancies. Curr Microbiol 1996; 33:118-22. [PMID: 8662183 DOI: 10.1007/s002849900085] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A "quasi-experimental" trial was carried out to investigate the effect of three antimicrobial regimens on oral and fecal yeast colonization in patients with hematologic malignancies. Fifty-four patients received ciprofloxacin and oral amphotericin B (group 1); 45 received ceftazidime, amikacin, vancomycin, and oral amphotericin B (group 2); and 30 received ceftazidime, amikacin, vancomycin, and intravenous amphotericin B (group 3). The oral yeast isolation rate showed a decrease in group 1 (from 59.3% to 40.7%) and group 3 (from 56.7% to 46.7%), and a marked increase in group 2 (from 51.1% to 84. 4%). All the groups showed a reduction in their fecal yeast isolation rate. An overgrowth of Candida parapsilosis, C. krusei, and C. tropicalis was observed in all the groups, but it was much higher in group 2. Our findings provide evidence that ceftazidime, amikacin, and vancomycin, given with oral amphotericin B, induce an overgrowth/persistence of Candida species in the mouth and gut, which might be attributable to inclusion of vancomycin. Treatment with intravenous amphotericin B has at least the capacity of counterbalancing yeast proliferation induced by that antibacterial regimen.
Collapse
Affiliation(s)
- D D'Antonio
- Dipartimento di Ematologia e della Trasfusione, Ospedale Civile di Pescara, Cattedra di Ematologia, Università "G. D'Annunzio," Chieti, Italia
| | | | | | | | | |
Collapse
|
24
|
D'Antonio D, Iacone A, Pierelli L, Bonfini T. Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Gruppo Italiano di Studio per la Manipolazione Cellulare in Ematologia. Eur J Clin Microbiol Infect Dis 1995; 14:552-6. [PMID: 7588835 DOI: 10.1007/bf02113440] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Recovery phase infection patterns in 55 patients who had undergone autologous blood progenitor cell transplantation (ABPCT) were evaluated retrospectively. The results were compared to those obtained in a group of 41 patients who received autologous bone marrow transplantation (ABMT). Fever related to documented or suspected infection developed in 38 of 55 patients in the ABPCT group and in 37 of 41 in the ABMT group (p < 0.05). The percentages of patients with positive blood cultures did not differ significantly (ABPCT, 8/55 vs. ABMT, 8/41, p > 0.05). However, fewer acquired systemic fungal infections (1/55 vs. 5/41, p < 0.05) as well as fewer days of antibiotic usage were observed in the ABPCT group.
Collapse
Affiliation(s)
- D D'Antonio
- Dipartimento di Ematologia e della Trasfusione, Ospedale Civile Pescara, Italy
| | | | | | | |
Collapse
|
25
|
Bavaro P, Bonfini T, Di Girolamo G, Angelini A, Di Bartolomeo P, Angrilli F, Papalinetti G, Olioso P, Torlontano G. CD8 serum levels in acute graft-versus-host disease diagnosis. J Clin Immunol 1994; 14:224-8. [PMID: 7929696 DOI: 10.1007/bf01552308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Attempts to identify an early and discriminating marker of acute graft-versus-host disease (aGvHD) have been unsuccessful. The levels of soluble CD4 and soluble CD8 in serum correlate with T cell subset activation and may be important in monitoring and characterizing immunological processes. We determined serum soluble CD4 (sCD4) and sCD8 levels with a two-site sandwich enzyme immunoassay on patients' serum samples collected prior to bone marrow transplantation and weekly after transplantation until day +28. No significant increment of sCD4 was documented in each determination. sCD8 rose significantly before diagnosis or development of maximal clinical symptoms in patients with grade II-III aGvHD than grade 0-I aGvHD [at day +21--median value 447 IU/ml; range 94-713; versus 1136 IU/ml, range 790-1416 (P = 0.002); at day +28--median value 443 IU/ml, range 73-992, versus 1164 IU/ml, range 625-1960 (P = 0.005)]. On the day of marrow infusion the sCD8 levels were significantly higher in patients who subsequently developed grade II-III than in patients with grade 0-I aGvHD (median value 155 IU/ml, range 10-332, versus 350 IU/ml, range 283-830; P = 0.003). Careful monitoring of sCD8 is a useful tool for a prompt aGvHD diagnosis and may be used in a clinical bone marrow transplantation setting.
Collapse
Affiliation(s)
- P Bavaro
- Dipartimento di Ematologia, Centro Trapianti Midollo, Ospedale Civile, Pescara, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Angelini A, Accorsi P, Iacone A, Bonfini T, Refè C, Olivieri A, Bodini U, Bergonzi C, Incarbone E, Adorno G. Concentration of human hematopoietic stem cells in bone marrow transplantation: results of a multicenter study using Baxter CS 3000 plus cell separator. Int J Artif Organs 1993; 16 Suppl 5:13-8. [PMID: 8013970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Preliminary BM processing to produce an enriched MNC fraction from large BM volumes improves subsequent pharmacological and/or immunological "ex vivo" treatment and cryopreservation. We detail on a multicenter study (6 Transplant Centers) performed to establish an effective and reliable protocol using a CS 3000 continuous flow separator on a large series of BM processed for autologous (96) and allogeneic (12) transplantation. The reduction in volume was 78.6 + 7.2% while 28.9 + 12.4% of the original nucleated cells were found in the final product. A mean of 84.3 + 13.2% of the staring MNC was yielded in a fraction containing over 81% MNC. Cloning efficiency indicated than the final graft was highly enriched in progenitor cells committed to the granulocyte/macrophage pathway (> 100%) as assessed in vitro (CFU-GM). Removal of RBC and PLT was 98.3 + 1.1 and 37.7 + 14.6%, respectively. The mean dose of MNC and CFU-GM was 0.6 + 0.37 x 10(8) and 0.96 + 1 x 10(5) recipient weight. The entire process was accomplished in 87.5 + 20 min. We concluded that this automated device is a simple and reproducible method for BM processing suitable as first step for further "ex vivo" automated negative and/or positive cell selections.
Collapse
Affiliation(s)
- A Angelini
- Servizio di Immunoematologia e Trasfusione Ospedale Civile, Pescara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|